Literature DB >> 15075329

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats.

Nadeem Wajih1, David C Sane, Susan M Hutson, Reidar Wallin.   

Abstract

The vitamin K-dependent gamma-carboxylation system is responsible for post-translational modification of vitamin K-dependent proteins, converting them to Gla-containing proteins. The system consists of integral membrane proteins located in the endoplasmic reticulum membrane and includes the gamma-carboxylase and the warfarin-sensitive enzyme vitamin K(1) 2,3-epoxide reductase (VKOR), which provides gamma-carboxylase with reduced vitamin K(1) cofactor. In this work, an in vitro gamma-carboxylation system was designed and used to understand how VKOR and gamma-carboxylase work together as a system and to identify factors that can regulate the activity of the system. Results are presented that demonstrate that the endoplasmic reticulum chaperone protein calumenin is associated with gamma-carboxylase and inhibits its activity. Silencing of the calumenin gene with siRNA resulted in a 5-fold increase in gamma-carboxylase activity. The results provide the first identification of a protein that can regulate the activity of the gamma-carboxylation system. The propeptides of vitamin K-dependent proteins stimulate gamma-carboxylase activity. Here we show that the factor X and prothrombin propeptides do not increase reduced vitamin K(1) cofactor production by VKOR in the system where VKOR is the rate-limiting step for gamma-carboxylation. These findings put calumenin in a central position concerning regulation of gamma-carboxylation of vitamin K-dependent proteins. Reduced vitamin K(1) cofactor transfer between VKOR and gamma-carboxylase is shown to be significantly impaired in the in vitro gamma-carboxylation system prepared from warfarin-resistant rats. Furthermore, the sequence of the 18-kDa subunit 1 of the VKOR enzyme complex was found to be identical in the two rat strains. This finding supports the notion that different forms of genetic warfarin resistance exist.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075329     DOI: 10.1074/jbc.M401645200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  siRNA silencing of calumenin enhances functional factor IX production.

Authors:  Nadeem Wajih; Susan M Hutson; Reidar Wallin
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

3.  Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection.

Authors:  Nadeem Wajih; John Owen; Reidar Wallin
Journal:  Thromb Res       Date:  2008-01-03       Impact factor: 3.944

Review 4.  Pharmacogenetics of warfarin: challenges and opportunities.

Authors:  Ming Ta Michael Lee; Teri E Klein
Journal:  J Hum Genet       Date:  2013-05-09       Impact factor: 3.172

5.  Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?

Authors:  Ingrid Glurich; Richard L Berg; James K Burmester
Journal:  Clin Med Res       Date:  2013-05-08

Review 6.  The future of warfarin pharmacogenetics in under-represented minority groups.

Authors:  Larisa H Cavallari; Minoli A Perera
Journal:  Future Cardiol       Date:  2012-07

Review 7.  Warfarin therapy: in need of improvement after all these years.

Authors:  Stephen E Kimmel
Journal:  Expert Opin Pharmacother       Date:  2008-04       Impact factor: 3.889

8.  Evaluation of genetic factors for warfarin dose prediction.

Authors:  Michael D Caldwell; Richard L Berg; Kai Qi Zhang; Ingrid Glurich; John R Schmelzer; Steven H Yale; Humberto J Vidaillet; James K Burmester
Journal:  Clin Med Res       Date:  2007-03

Review 9.  Warfarin Pharmacogenetics: New Life for an Old Drug.

Authors:  Ming-Shien Wen; Ming Ta Michael Lee
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

10.  Calumenin but not reticulocalbin forms a Ca2+-dependent complex with thrombospondin-1. A potential role in haemostasis and thrombosis.

Authors:  Gry Aune Westergaard Hansen; Henrik Vorum; Christian Jacobsen; Bent Honoré
Journal:  Mol Cell Biochem       Date:  2008-08-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.